customContents

entityId

entityUuid

articlePageQuery

filter

article

articleBaseAdvertisingInfoArticle

articleListArticle

articleSeoArticle

helpersCheckIsPostiesArticle

hooksArticleAcknowledgementGateOverlayArticle

hooksTrackPageViewArticle

hooksContentInterestArticle

articleLinkingDataContent

articleSchemaContent

liveArticle

advertZone

sentiment

contentLock

topics

types

sections

moreOnThisArticles

urlAlias

commentCount

sponsorType

authorLocations

authors

paywallTypes

corrections

displaySlideShow

multimediaEmbed

printHeadline

seriesContainer

socialHeadline

headline

flag

firstTopic

glossary

flattenTypeIds

publishedDate

additionalInfoBoxes

images

image

relatedLinks

relatedNewsletters

__typename

createdDate

sponsor

factSheets

series

knowledgeQuestion

disableOffPlatformContent

published

updatedDate

summary

subHeadline

body

keywords

copyrighted

customTimezone

liveContents

British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the lives of millions of people”.
The “major advance” in treatment offers a completely new drug approach to treating the condition, which can cause terrifying hallucinations, delusional thoughts and social withdrawal.
The US Food and Drug Administration (FDA) has approved the new drug Cobenfy, which is owned by American pharmaceutical firm Bristol Myers Squibb.
The FDA’s approval was based on data from two studies showing patients experienced fewer schizophrenia symptoms.

The drug is the first approved antipsychotic to target receptors in the brain and body associated with the cholinergic neurotransmitter system, which has a key role in learning and memory, digestion, control of heartbeat, blood pressure, movement, and other functions.
In the UK, the University of Oxford has said it will start a trial on the compound in 2025.
A spokesperson for Bristol Myers Squibb said it had only submitted the drug to the FDA so far but continued “to evaluate our opportunities outside of the US”.
Dr Lynsey Bilsland, head of mental health translation at Wellcome, an independent global charitable foundation in the UK that funded early studies into Cobenfy, said: “It works in a completely different way from any other currently used schizophrenia drugs. It has the potential to change the lives of millions of people.”
While schizophrenia is commonly treated with antipsychotics, which can be effective in managing symptoms such as hallucinations and delusions, they do not address other life-limiting symptoms such as social withdrawal and memory problems.
“Cobenfy has the potential to address all of the above symptoms and also has fewer side effects, such as sleepiness and weight gain, and therefore could be game-changing, especially for those for whom other drugs do not work,” Bilsland said.
“Cobenfy is an outstanding example of how science can drive forward more effective mental health treatments in our lifetimes.”
In my opinion, as a clinician and researcher, this is possibly one of the most exciting developments in our field
Dr Sameer Jauhar, senior clinical lecturer in affective disorders and psychosis, King’s College London
Dr Robert McCutcheon, from the University of Oxford’s department of psychiatry, called the drug a major advance – “the first treatment for schizophrenia with a novel target for 70 years”.
“Current treatments are ineffective for many of the symptoms of schizophrenia – we need compounds with novel mechanisms of action,” he said.
“All other treatments work by targeting dopamine receptors. This is the first treatment that has a different target.
“We hope this may mean it can help people who don’t respond to standard treatments.”
Dr Sameer Jauhar, senior clinical lecturer in affective disorders and psychosis at King’s College London, said: “Schizophrenia can be a devastating illness for people and their families, and the effects on society are significant.”
Jauhar, who is also a consultant psychiatrist at the South London and Maudsley NHS Foundation Trust, added that effective treatments are available, and the drugs used are a foundation for holistic care that includes psychosocial interventions – activities used to modify behaviour, emotional state or feeling.
“Unfortunately, currently available antipsychotics have significant side effects, which include weight gain and movement effects,” he said, noting this can affect patients’ willingness to stick with agreed treatment.
“All currently licensed antipsychotics exert effects on the dopamine system, and this has been the case for at least 50 years.”
Jauhar said that there have been “false dawns” before, and that despite significant efforts in the field – with significant financial investment – phase-three trials of newer compounds have so far been disappointing.
“This novel treatment is the first of its kind, which does not act directly on the dopamine system, with good phase-three trial data,” he said.
“In my opinion, as a clinician and researcher, this is possibly one of the most exciting developments in our field.”
Schizophrenia is a severe, long-term mental health condition.
In Hong Kong, the Hospital Authority says it affects about 1 per cent of the local population. The World Health Organization estimates that it affects about 24 million people, or 1 in 300 people, worldwide. People with schizophrenia have a life expectancy 10 to 20 years below that of the general population.
Like what you read? Follow SCMP Lifestyle on Facebook, X and Instagram. You can also sign up for our eNewsletter here.


Experts hail new schizophrenia drug Cobenfy as a game-changer, the ‘first of its kind’

Parents mark 30 years since their organ donation after son died changed attitudes in Italy

The everyday foods and drinks that could lower your dementia risk, and how much to have

From ECGs to AI, advances in diagnosis and treatment of heart disease and how to prevent it

Wellness

The new schizophrenia drug Cobenfy has been approved by the US Food and Drug Administration and has experts excited over its potential. Photo: Bristol Myers Squibb


Experts hope the new schizophrenia drug may help patients who do not respond well to existing treatments. Photo: Shutterstock

How positive ageing helps you age well, from lower disease risk to quicker recoveries

Pilates instructor Beth Narain practises at her gym in South Bay, Hong Kong. She explains how she stays positive about ageing - something that both studies and celebrities including Martha Stewart and Paulina Porizkova agree helps you age well. Photo: Jonathan Wong

Narain on holiday in the UK. Photo: Beth Narain

Narain is a former ballet dancer. Photo: Beth Narain

Paulina Porizkova in a campaign for Australian brand Camilla and Marc in 2021. Photo: Camilla and Marc

The Sports Illustrated swimsuit issue 2023, with Martha Stewart on the cover. Photo: TNS

Soon to be 78, Narain has a positive view of ageing.  Photo: Beth Narain

Advances in technology are making it easier to view the heart in greater detail. 
Photo: Shutterstock


Getting outdoors is a great way to prevent cardiovascular disease. Cardiologists explain other ways to safeguard heart health and risks, as we look at advances in heart medicine for World Heart Day. Photo: Shutterstock

Cardiology has come a long way in a short time, with technological advances making it easier than ever to detect and treat heart-related issues. Artificial intelligence is now being harnessed in heart health. Photo: Shutterstock

Professor Charalambos Antoniades is the British Heart Foundation chair of cardiovascular medicine at Oxford. Photo: facebook.com/bhf

Dr Jagat Narula, president-elect of the World Heart Federation. Photo: World Heart Federation

Dr Boon Lim is a London-based consultant cardiologist and electrophysiologist. Photo: Dr Boon Lim

Lim recommends walking or sitting in silence in nature, without distraction from digital devices – a practice known as forest bathing. Photo: Shutterstock

How to end your addiction to your smartphone using Hong Kong expert’s 5 tips

Red lights shine on the ground  in Hong Kong to warn smartphone-using pedestrians about traffic signals. Smartphone addiction causes multiple problems, and we should all reduce our use of the gadgets, a psychologist says. Photo: Hong Kong Transport Department

Hong Kong parents are struggling to control their children’s overuse of gadgets. Photo: Shutterstock

Smartphone use may cause problems with emotional regulation and cognitive function, impulsivity, and low self-esteem in young adults and teens, according to Hong Kong-based psychologist Quratulain Zaidi. Photo: Bloomberg

People should be more aware of the dangers of smartphone overuse, says Quratulain Zaidi, Hong Kong-based psychologist. Photo: Quratulain Zaidi

Many young adults use their smartphones in bed, affecting the quality of their sleep. Photo: Shutterstock

Avoid using your smartphone in the toilet if you want to get control over your digital dependence. Photo: Shutterstock

Anne Hathaway’s weight loss journey: anti-inflammatory diet, intense exercise key to actress’ transformation for Catwoman in The Dark Knight Rises

Anne Hathaway at a Valentino fashion show in Rome, Italy, in 2022. The actresshas talked about how she lost weight for her various movie roles. Photo: Getty Images

Hathaway as Catwoman in a still from The Dark Knight Rises. Photo: Warner Bros

To control her blood sugar, Hathaway ate avocados, almonds, sesame seeds, plain chocolate, bright red and orange vegetables high in antioxidants like yams, dark leafy greens, plus ginger and turmeric. Photo: Shutterstock

Hathaway on the set of The Devil Wears Prada. Photo: Getty Images 

Hathaway in a still from Les Misérables. Photo: Universal Pictures

Lifestyle

Health & Wellness

Health

Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer side effects


Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer side effects.


Medicine

Disease

Mental health